tweetindex
ES

Nature Reviews Drug Discovery

@NatRevDrugDisc · London · joined 28 Apr 2009

Editorial team of Nature Reviews Drug Discovery.

44 942Followers
469Following
4 172Posts total
56.7KViews on collected posts

Últimas publicaciones

The FDA recently approved the first orexin receptor agonist for narcolepsy https://t.co/xrqJVAIRDr Oveporexton is anticipated to transform the treatment of this sleep disorder, and potential additional applications have led to the class being dubbed the GLP-1s of neuroscience ht 2.8K views · 32 likes · 6 reposts · 1 replies Open on X →
@NatRevDrugDisc @iu22ie33 And the explanation. 451 views · 0 likes · 0 reposts · 0 replies Open on X →
For readers interested in the opportunities and pitfalls for CAR-T therapies for autoimmune diseases, here's a recent comprehensive review https://t.co/RNbKBGRrgm https://t.co/b3JOpR4MI7 9.1K views · 167 likes · 49 reposts · 1 replies Open on X →
Solute carrier membrane transporters: emerging targets in CNS disorders https://t.co/0RpeFcducw https://t.co/YZV9hQkg2I This new Review discusses targeting SLC transporters in neurodegenerative diseases, autism spectrum disorders and epilepsy https://t.co/fFE3YiKZy8 2.9K views · 40 likes · 12 reposts · 1 replies Open on X →
For readers interested in JAK inhibitors for autoimmmune diseases, such as Roivant's brepocitinib that has just been approved by the FDA for dermatomyositis, here's a review on pharmacological targeting of the JAK-STAT pathway https://t.co/mRjeD1BGoN https://t.co/b3NdcHcPJc https 9.7K views · 167 likes · 50 reposts · 0 replies Open on X →
Our September issue is live! Read about brain-shuttle biologics, targeting claudins in cancer, agonist antibody-based immunotherapies, autophagy modulation in cancer and more here https://t.co/kWQJeeYbZr https://t.co/AhUat2jkMB 2.1K views · 24 likes · 7 reposts · 0 replies Open on X →
Andy Blidy Caravello A and Blidy A (2026) A proposed convergent molecular chain linking senescence, cancer, and chronic infection to a correctable failure of dendritic cell instruction. Front. Immunol. 17:1861044. doi: 10.3389/fimmu.2026.1861044 COPYRIGHT © 2026 HYPOTHESIS AND 29.7K views · 30 likes · 10 reposts · 3 replies Open on X →

Frente a cuentas del mismo tamaño

7 publicaciones de los últimos 90 días, junto al rango de 10K–100K seguidores. llega a mucha gente, pero pocos de esos espectadores reaccionan.

Visualizaciones medianas2 873esta cuenta877mediana de 10K–100K
Alcance, %6.39%esta cuenta3.26%mediana de 10K–100K
Interacción, %1.47%esta cuenta2.00%mediana de 10K–100K
MétricaEsta cuentaMediana de 10K–100KProporción
Visualizaciones medianas por publicación2 8738773.28×
Alcance (visualizaciones ÷ seguidores)6.39%3.26%1.96×
Tasa de interacción1.47%2.00%0.74×

Otras cuentas de este rango →   Comparar con otra cuenta →   Cómo se construyen estas referencias →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

29.7K15 Aug
2.1K28 Aug
9.7K1 Sep
2.9K2 Sep
9.1K3 Sep
451
2.8K4 Sep

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.15%15 Aug
1.47%28 Aug
2.25%1 Sep
1.84%2 Sep
2.38%3 Sep
0.00%
1.39%4 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 2.00%.

What the audience does

Likes58.3%460 in total
Reposts17.0%134 in total
Replies0.8%6 in total
Quotes0.4%3 in total
Bookmarks23.6%186 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Cuentas similares